Type 2 Diabetes News and Research

Latest Type 2 Diabetes News and Research

Research reveals financial toll of living with type 2 diabetes

In a first-of-its-kind study, researchers used a unique dataset to show that patients with type 2 diabetes have significantly worse financial outcomes than other patients.

28 Jul 2025

Marbling of fat inside muscles found to block healing and weaken strength

Consider the delicate web of fat in a Wagyu steak. The "marbling" that makes carnivore connoisseurs swoon is a visual heuristic for quality flavor.

28 Jul 2025

Which GLP-1 meds have the most side effects? Study of 60,000 Facebook posts gives answers

Researchers analyzed nearly 60,000 public Facebook posts to identify real-world adverse events linked to GLP-1 receptor agonist (GLP-1 RA) medications. Gastrointestinal symptoms were most common, while mental health concerns and tirzepatide-specific side effects were also flagged.

28 Jul 2025

Experts say you don’t need 10,000 steps, here’s the new magic number

A major systematic review finds that walking just 7,000 steps per day, rather than the traditional 10,000, can significantly reduce the risk of mortality, cardiovascular disease, dementia, and more. The analysis, published in The Lancet Public Health, provides an evidence-based and achievable target for adult health.

27 Jul 2025

Heavy smoking linked to atrophy in Alzheimer’s brain regions

MRI findings indicate that smoking is linked to reduced brain volume, raising concerns about dementia risk, especially with higher body mass index.

25 Jul 2025

Commonly used type 2 diabetes medication linked to higher rate of heart-related conditions

New research from investigators at Mass General Brigham suggests that a commonly used type 2 diabetes medication is linked to a higher rate of heart-related conditions compared to medications that hit other targets.

24 Jul 2025

Walking 7,000 steps per day associated with reductions in risk of several serious health problems

A comprehensive new study analyzing data from over 160,000 adults finds that walking approximately 7,000 steps per day is associated with reductions in the risk of several serious health outcomes, including all-cause mortality (47% reduction), cardiovascular disease (25% reduction), cancer (6% reduction), type 2 diabetes (14% reduction), dementia (38% reduction), depression (22% reduction), and falls (28% reduction).

24 Jul 2025

What happens to your weight after quitting GLP-1 anti-obesity drugs?

Stopping anti-obesity medications leads to significant weight regain, starting as early as eight weeks and stabilizing by six months. Despite this rebound, most patients maintain some weight loss compared to baseline a year after discontinuation.

23 Jul 2025

UN proposal on trans fats could harm nutrition in poor countries, experts warn

A draft UN declaration to eliminate trans-fatty acids from global diets has elicited a sharp reaction from experts who claim it violates the rights of the world's poorest to nutritional benefits of milk and meat.

23 Jul 2025

Chinese study shows lasting weight loss after tirzepatide treatment

Obesity has become a global epidemic, contributing to a host of chronic health conditions such as type 2 diabetes, hypertension, and cardiovascular disease.

23 Jul 2025

EU initiative puts nutrition at the heart of diabetes care

Managing type 2 diabetes isn't just about medicine—it's also about what's on your plate. Cook2DIAbeat is a new EU-supported initiative that puts food front and centre in the fight against diabetes.

23 Jul 2025

Can one drug do it all? Reviewing the expanding clinical universe of GLP-1 agonists

Landmark trials have shown that GLP-1 receptor agonists, originally developed for diabetes and weight loss, also provide significant benefits for cardiovascular, kidney, liver, joint, and sleep-related diseases. These effects extend beyond weight loss, suggesting anti-inflammatory mechanisms with broad potential for managing chronic diseases.

22 Jul 2025

GLP-1 receptor agonists linked to lower dementia risk in type 2 diabetes

GLP-1 receptor agonists, a class of drug used to treat type 2 diabetes, likely trump the widely prescribed metformin for curbing dementia risk in people with the condition, finds the largest study of its kind, published in the open access journal BMJ Open Diabetes Research & Care.

22 Jul 2025